{
    "id": 1549,
    "fullName": "ERBB2 T798M",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) T798M lies within the gatekeeper position in the ATP binding site of the Erbb2 (Her2) protein. T798M results in activation of the Erbb2 (Her2) protein in cell culture experiments (PMID: 22046346, PMID: 23948973) and demonstrates the ability to increase cell proliferation and cell viability in culture (PMID: 29533785).",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                },
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "T798M",
    "createDate": "08/29/2014",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 170778,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724811_39724812delCAinsTG",
        "cDna": "c.2393_2394delCAinsTG",
        "protein": "p.T798M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2046,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 622,
                "therapyName": "AEE788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 2911,
                "therapyName": "EKI-285",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 962,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells expressing ERBB2 (HER2) T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 1415,
                "therapyName": "Trastuzumab + XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 957,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 1672,
                "therapyName": "Cetuximab + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 955,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 961,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973).",
            "molecularProfile": {
                "id": 1572,
                "profileName": "ERBB2 T798M"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 954,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973).",
            "molecularProfile": {
                "id": 23649,
                "profileName": "ERBB2 T798M ERBB2 amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 624,
                    "pubMedId": 23948973,
                    "title": "Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23948973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1572,
            "profileName": "ERBB2 T798M",
            "profileTreatmentApproaches": [
                {
                    "id": 4494,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 T798M"
                },
                {
                    "id": 4493,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 T798M"
                }
            ]
        },
        {
            "id": 23649,
            "profileName": "ERBB2 T798M ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170779,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724811_39724812delCAinsTG",
            "cDna": "c.2393_2394delCAinsTG",
            "protein": "p.T798M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170778,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724811_39724812delCAinsTG",
            "cDna": "c.2393_2394delCAinsTG",
            "protein": "p.T798M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}